IMR Press / EJGO / Special Issues / 1629771306213

Gynecological Oncology Treatment: Recent Progress in Clinical Modalities

Submission deadline: 28 February 2022
Special Issue Editors
Osamu Hiraike, MD, PhD
Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan
Interests: Pathophysiology of the Human Reproduction and Ovary; Reproductive Endocrinology; Benign Gynecological Tumors; Minimally Invasive Gynecological Surgery and Endoscopy; Repair of Pelvic Floor; Breast Cancer; Endometrial Cancer
Kenbun Sone, PhD
Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
Interests: Epigenetic Mechanism in gynecologic oncology
Special Issue Information

Dear Colleagues,

Gynecological cancer including uterine cervical cancer, endometrial cancer and ovarian cancer constitutes unique disease properties. Representative recent topics of uterine cervical cancer are real world evidence of human papilloma virus vaccine and application of minimally invasive surgery (MIS). Treatment for early-stage endometrial cancer is almost established using MIS, and laparoscopic surgery and robotic surgery exhibit pronounced development and establishment of safety of these surgeries are crucial for patients. Another focus on epidemiology of endometrial cancer is the presence of familial trait that include Lynch syndrome. Recent molecular and genetic analysis of ovarian cancer is remarkable, and adjuvant chemotherapy for ovarian cancer became completely different from those of ten years ago. Artificial intelligence (AI) modalities might extend and expand human intelligence, and diagnostic significance of AI technology is steady progressing. Another remarkable issue related to gynecological cancer is the finding of gene fusions that are thought to be driver mutations. Oncology panel is developed and is supposed to be promising candidate modality to find the suitable drugs for unusual gynecologic tumors.
In this special issue, the authors will present novel and the most recent studies with regard to the development of gynecological cancers. These include the molecular characterization of gynecological cancers, treatment strategies of various gynecological cancers, application, ingenuity and limitation of MIS, and advances of diagnostic modalities (AI and oncology panel). 

Dr. Osamu Hiraike and Dr. Kenbun Sone

Guest Editors

Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Oncology Panel
Molecular Classification
Hereditary Gynecological Cancer
Minimally Invasive Therapy
Robotic Surgery
Artificial Intelligence Technology
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top